---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-022764"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T11:26:30.458485+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates

## Summary
- FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).
- FY2024 net loss $76.4M ($0.63 basic EPS) vs $143.1M ($1.25) prior year; cash $109.1M (Dec 2024) vs $192.4M.
- Phase 3 SENTRY myelofibrosis trial: endpoint updated to Abs-TSS; top-line data expected 2H 2025; enrollment complete 1H 2025.
- Phase 3 XPORT-EC-042 endometrial cancer trial modified: focus on pMMR/dMMR ineligible for checkpoint inhibitors; sample size 276; data mid-2026.
- FY2025 guidance: total revenue $140-155M; US XPOVIO net product rev $115-130M; R&D+SG&A $240-255M.

## SEC filing metadata
- accession: 0000950170-25-022764
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/0000950170-25-022764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/kpti-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-022764
- JSON: https://secwatch.observer/filing/0000950170-25-022764.json
- Plain text: https://secwatch.observer/filing/0000950170-25-022764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.